Renalytix PLC Notice of Q3 Results
May 09 2024 - 1:00AM
RNS Regulatory News
RNS Number : 6885N
Renalytix PLC
09 May 2024
Renalytix plc
("Renalytix" or the
"Company")
Renalytix to Report Financial Results for
Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE
CITY, May 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE:
RENX) announces that it will report its third quarter fiscal year
2024 financial results on Wednesday, May 15, 2024 before U.S.
market open. The Company will host a corresponding conference call
and live webcast to discuss the financial results and key topics
including business strategy, partnerships and regulatory and
reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the
day.
Conference Call
Details:
To participate in the live conference call via telephone, please
register here.
Upon registering, a dial-in number and unique PIN will be provided
in order for interested parties to join the conference call.
Webcast Registration
link: https://edge.media-server.com/mmc/p/k57ufszy
For further information,
please contact:
Renalytix plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook
PR
|
|
|
Stifel (Nominated Adviser, Joint Broker)
|
Tel: 020 7710
7600
|
Alex Price / Nicholas Moore / Nick
Harland / Samira Essebiyea
|
|
|
|
Investec Bank plc (Joint Broker)
|
Tel: 020 7597
4000
|
Gary Clarence / Shalin
Bhamra
|
|
|
|
Walbrook PR Limited
|
Tel: 020 7933
8780 or
renalytix@walbrookpr.com
|
Paul McManus / Alice
Woodings
|
Mob: 07980
541 893 / 07407 804 654
|
|
|
CapComm Partners
|
|
Peter DeNardo
|
Tel:
415-389-6400 or
investors@renalytix.com
|
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORSSFFMAELSELI
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024